drugset
drugset / Trial / NCT00006020

S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia

NCT00006020 ↗

Phase 2 Completed 35 enrolled SWOG Cancer Research Network National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory acute lymphocytic leukemia.

Timeline

Start
2000-07
Primary completion
2004-06
Completion
2004-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Nelarabine Small molecule 1.5 g Intravenous

Indications

leukemia